Global Insulin Biosimilars Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Page: 102

Published Date: 26 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.

According to our (Global Info Research) latest study, the global Insulin Biosimilars market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Insulin Biosimilars market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Insulin Biosimilars market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Insulin Biosimilars market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Insulin Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Insulin Biosimilars market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Insulin Biosimilars
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Insulin Biosimilars market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., Novo Nordisk A/S and Biocon, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation
Insulin Biosimilars market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Rapid-Acting Biosimilars
    Long-Acting Biosimilars
    Premixed Biosimilars

Market segment by Application
    Type I Diabetes
    Type II Diabetes

Major players covered
    Sanofi S.A.
    Boehringer Ingelheim
    Eli Lilly & Co.
    Novo Nordisk A/S
    Biocon
    Geropharm
    Wockhardt
    Gan&Lee Pharmaceuticals
    The United Laboratories International
    Tonghua Dongbao Pharmaceutical

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Insulin Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Insulin Biosimilars, with price, sales, revenue and global market share of Insulin Biosimilars from 2018 to 2023.
Chapter 3, the Insulin Biosimilars competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Insulin Biosimilars breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Insulin Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Insulin Biosimilars.
Chapter 14 and 15, to describe Insulin Biosimilars sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Insulin Biosimilars
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Insulin Biosimilars Consumption Value by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Rapid-Acting Biosimilars
        1.3.3 Long-Acting Biosimilars
        1.3.4 Premixed Biosimilars
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Insulin Biosimilars Consumption Value by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Type I Diabetes
        1.4.3 Type II Diabetes
    1.5 Global Insulin Biosimilars Market Size & Forecast
        1.5.1 Global Insulin Biosimilars Consumption Value (2018 & 2022 & 2029)
        1.5.2 Global Insulin Biosimilars Sales Quantity (2018-2029)
        1.5.3 Global Insulin Biosimilars Average Price (2018-2029)

2 Manufacturers Profiles
    2.1 Sanofi S.A.
        2.1.1 Sanofi S.A. Details
        2.1.2 Sanofi S.A. Major Business
        2.1.3 Sanofi S.A. Insulin Biosimilars Product and Services
        2.1.4 Sanofi S.A. Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Sanofi S.A. Recent Developments/Updates
    2.2 Boehringer Ingelheim
        2.2.1 Boehringer Ingelheim Details
        2.2.2 Boehringer Ingelheim Major Business
        2.2.3 Boehringer Ingelheim Insulin Biosimilars Product and Services
        2.2.4 Boehringer Ingelheim Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Boehringer Ingelheim Recent Developments/Updates
    2.3 Eli Lilly & Co.
        2.3.1 Eli Lilly & Co. Details
        2.3.2 Eli Lilly & Co. Major Business
        2.3.3 Eli Lilly & Co. Insulin Biosimilars Product and Services
        2.3.4 Eli Lilly & Co. Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Eli Lilly & Co. Recent Developments/Updates
    2.4 Novo Nordisk A/S
        2.4.1 Novo Nordisk A/S Details
        2.4.2 Novo Nordisk A/S Major Business
        2.4.3 Novo Nordisk A/S Insulin Biosimilars Product and Services
        2.4.4 Novo Nordisk A/S Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Novo Nordisk A/S Recent Developments/Updates
    2.5 Biocon
        2.5.1 Biocon Details
        2.5.2 Biocon Major Business
        2.5.3 Biocon Insulin Biosimilars Product and Services
        2.5.4 Biocon Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Biocon Recent Developments/Updates
    2.6 Geropharm
        2.6.1 Geropharm Details
        2.6.2 Geropharm Major Business
        2.6.3 Geropharm Insulin Biosimilars Product and Services
        2.6.4 Geropharm Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Geropharm Recent Developments/Updates
    2.7 Wockhardt
        2.7.1 Wockhardt Details
        2.7.2 Wockhardt Major Business
        2.7.3 Wockhardt Insulin Biosimilars Product and Services
        2.7.4 Wockhardt Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Wockhardt Recent Developments/Updates
    2.8 Gan&Lee Pharmaceuticals
        2.8.1 Gan&Lee Pharmaceuticals Details
        2.8.2 Gan&Lee Pharmaceuticals Major Business
        2.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
        2.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Gan&Lee Pharmaceuticals Recent Developments/Updates
    2.9 The United Laboratories International
        2.9.1 The United Laboratories International Details
        2.9.2 The United Laboratories International Major Business
        2.9.3 The United Laboratories International Insulin Biosimilars Product and Services
        2.9.4 The United Laboratories International Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 The United Laboratories International Recent Developments/Updates
    2.10 Tonghua Dongbao Pharmaceutical
        2.10.1 Tonghua Dongbao Pharmaceutical Details
        2.10.2 Tonghua Dongbao Pharmaceutical Major Business
        2.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
        2.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Insulin Biosimilars by Manufacturer
    3.1 Global Insulin Biosimilars Sales Quantity by Manufacturer (2018-2023)
    3.2 Global Insulin Biosimilars Revenue by Manufacturer (2018-2023)
    3.3 Global Insulin Biosimilars Average Price by Manufacturer (2018-2023)
    3.4 Market Share Analysis (2022)
        3.4.1 Producer Shipments of Insulin Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2022
        3.4.2 Top 3 Insulin Biosimilars Manufacturer Market Share in 2022
        3.4.2 Top 6 Insulin Biosimilars Manufacturer Market Share in 2022
    3.5 Insulin Biosimilars Market: Overall Company Footprint Analysis
        3.5.1 Insulin Biosimilars Market: Region Footprint
        3.5.2 Insulin Biosimilars Market: Company Product Type Footprint
        3.5.3 Insulin Biosimilars Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Insulin Biosimilars Market Size by Region
        4.1.1 Global Insulin Biosimilars Sales Quantity by Region (2018-2029)
        4.1.2 Global Insulin Biosimilars Consumption Value by Region (2018-2029)
        4.1.3 Global Insulin Biosimilars Average Price by Region (2018-2029)
    4.2 North America Insulin Biosimilars Consumption Value (2018-2029)
    4.3 Europe Insulin Biosimilars Consumption Value (2018-2029)
    4.4 Asia-Pacific Insulin Biosimilars Consumption Value (2018-2029)
    4.5 South America Insulin Biosimilars Consumption Value (2018-2029)
    4.6 Middle East and Africa Insulin Biosimilars Consumption Value (2018-2029)

5 Market Segment by Type
    5.1 Global Insulin Biosimilars Sales Quantity by Type (2018-2029)
    5.2 Global Insulin Biosimilars Consumption Value by Type (2018-2029)
    5.3 Global Insulin Biosimilars Average Price by Type (2018-2029)

6 Market Segment by Application
    6.1 Global Insulin Biosimilars Sales Quantity by Application (2018-2029)
    6.2 Global Insulin Biosimilars Consumption Value by Application (2018-2029)
    6.3 Global Insulin Biosimilars Average Price by Application (2018-2029)

7 North America
    7.1 North America Insulin Biosimilars Sales Quantity by Type (2018-2029)
    7.2 North America Insulin Biosimilars Sales Quantity by Application (2018-2029)
    7.3 North America Insulin Biosimilars Market Size by Country
        7.3.1 North America Insulin Biosimilars Sales Quantity by Country (2018-2029)
        7.3.2 North America Insulin Biosimilars Consumption Value by Country (2018-2029)
        7.3.3 United States Market Size and Forecast (2018-2029)
        7.3.4 Canada Market Size and Forecast (2018-2029)
        7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe
    8.1 Europe Insulin Biosimilars Sales Quantity by Type (2018-2029)
    8.2 Europe Insulin Biosimilars Sales Quantity by Application (2018-2029)
    8.3 Europe Insulin Biosimilars Market Size by Country
        8.3.1 Europe Insulin Biosimilars Sales Quantity by Country (2018-2029)
        8.3.2 Europe Insulin Biosimilars Consumption Value by Country (2018-2029)
        8.3.3 Germany Market Size and Forecast (2018-2029)
        8.3.4 France Market Size and Forecast (2018-2029)
        8.3.5 United Kingdom Market Size and Forecast (2018-2029)
        8.3.6 Russia Market Size and Forecast (2018-2029)
        8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific
    9.1 Asia-Pacific Insulin Biosimilars Sales Quantity by Type (2018-2029)
    9.2 Asia-Pacific Insulin Biosimilars Sales Quantity by Application (2018-2029)
    9.3 Asia-Pacific Insulin Biosimilars Market Size by Region
        9.3.1 Asia-Pacific Insulin Biosimilars Sales Quantity by Region (2018-2029)
        9.3.2 Asia-Pacific Insulin Biosimilars Consumption Value by Region (2018-2029)
        9.3.3 China Market Size and Forecast (2018-2029)
        9.3.4 Japan Market Size and Forecast (2018-2029)
        9.3.5 Korea Market Size and Forecast (2018-2029)
        9.3.6 India Market Size and Forecast (2018-2029)
        9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
        9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America
    10.1 South America Insulin Biosimilars Sales Quantity by Type (2018-2029)
    10.2 South America Insulin Biosimilars Sales Quantity by Application (2018-2029)
    10.3 South America Insulin Biosimilars Market Size by Country
        10.3.1 South America Insulin Biosimilars Sales Quantity by Country (2018-2029)
        10.3.2 South America Insulin Biosimilars Consumption Value by Country (2018-2029)
        10.3.3 Brazil Market Size and Forecast (2018-2029)
        10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa
    11.1 Middle East & Africa Insulin Biosimilars Sales Quantity by Type (2018-2029)
    11.2 Middle East & Africa Insulin Biosimilars Sales Quantity by Application (2018-2029)
    11.3 Middle East & Africa Insulin Biosimilars Market Size by Country
        11.3.1 Middle East & Africa Insulin Biosimilars Sales Quantity by Country (2018-2029)
        11.3.2 Middle East & Africa Insulin Biosimilars Consumption Value by Country (2018-2029)
        11.3.3 Turkey Market Size and Forecast (2018-2029)
        11.3.4 Egypt Market Size and Forecast (2018-2029)
        11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
        11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics
    12.1 Insulin Biosimilars Market Drivers
    12.2 Insulin Biosimilars Market Restraints
    12.3 Insulin Biosimilars Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry
    12.5 Influence of COVID-19 and Russia-Ukraine War
        12.5.1 Influence of COVID-19
        12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain
    13.1 Raw Material of Insulin Biosimilars and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Insulin Biosimilars
    13.3 Insulin Biosimilars Production Process
    13.4 Insulin Biosimilars Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Insulin Biosimilars Typical Distributors
    14.3 Insulin Biosimilars Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Insulin Biosimilars Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Insulin Biosimilars Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
    Table 4. Sanofi S.A. Major Business
    Table 5. Sanofi S.A. Insulin Biosimilars Product and Services
    Table 6. Sanofi S.A. Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 7. Sanofi S.A. Recent Developments/Updates
    Table 8. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
    Table 9. Boehringer Ingelheim Major Business
    Table 10. Boehringer Ingelheim Insulin Biosimilars Product and Services
    Table 11. Boehringer Ingelheim Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 12. Boehringer Ingelheim Recent Developments/Updates
    Table 13. Eli Lilly & Co. Basic Information, Manufacturing Base and Competitors
    Table 14. Eli Lilly & Co. Major Business
    Table 15. Eli Lilly & Co. Insulin Biosimilars Product and Services
    Table 16. Eli Lilly & Co. Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 17. Eli Lilly & Co. Recent Developments/Updates
    Table 18. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
    Table 19. Novo Nordisk A/S Major Business
    Table 20. Novo Nordisk A/S Insulin Biosimilars Product and Services
    Table 21. Novo Nordisk A/S Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 22. Novo Nordisk A/S Recent Developments/Updates
    Table 23. Biocon Basic Information, Manufacturing Base and Competitors
    Table 24. Biocon Major Business
    Table 25. Biocon Insulin Biosimilars Product and Services
    Table 26. Biocon Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 27. Biocon Recent Developments/Updates
    Table 28. Geropharm Basic Information, Manufacturing Base and Competitors
    Table 29. Geropharm Major Business
    Table 30. Geropharm Insulin Biosimilars Product and Services
    Table 31. Geropharm Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 32. Geropharm Recent Developments/Updates
    Table 33. Wockhardt Basic Information, Manufacturing Base and Competitors
    Table 34. Wockhardt Major Business
    Table 35. Wockhardt Insulin Biosimilars Product and Services
    Table 36. Wockhardt Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 37. Wockhardt Recent Developments/Updates
    Table 38. Gan&Lee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 39. Gan&Lee Pharmaceuticals Major Business
    Table 40. Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
    Table 41. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 42. Gan&Lee Pharmaceuticals Recent Developments/Updates
    Table 43. The United Laboratories International Basic Information, Manufacturing Base and Competitors
    Table 44. The United Laboratories International Major Business
    Table 45. The United Laboratories International Insulin Biosimilars Product and Services
    Table 46. The United Laboratories International Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 47. The United Laboratories International Recent Developments/Updates
    Table 48. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 49. Tonghua Dongbao Pharmaceutical Major Business
    Table 50. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
    Table 51. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 52. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
    Table 53. Global Insulin Biosimilars Sales Quantity by Manufacturer (2018-2023) & (K Units)
    Table 54. Global Insulin Biosimilars Revenue by Manufacturer (2018-2023) & (USD Million)
    Table 55. Global Insulin Biosimilars Average Price by Manufacturer (2018-2023) & (USD/Unit)
    Table 56. Market Position of Manufacturers in Insulin Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
    Table 57. Head Office and Insulin Biosimilars Production Site of Key Manufacturer
    Table 58. Insulin Biosimilars Market: Company Product Type Footprint
    Table 59. Insulin Biosimilars Market: Company Product Application Footprint
    Table 60. Insulin Biosimilars New Market Entrants and Barriers to Market Entry
    Table 61. Insulin Biosimilars Mergers, Acquisition, Agreements, and Collaborations
    Table 62. Global Insulin Biosimilars Sales Quantity by Region (2018-2023) & (K Units)
    Table 63. Global Insulin Biosimilars Sales Quantity by Region (2024-2029) & (K Units)
    Table 64. Global Insulin Biosimilars Consumption Value by Region (2018-2023) & (USD Million)
    Table 65. Global Insulin Biosimilars Consumption Value by Region (2024-2029) & (USD Million)
    Table 66. Global Insulin Biosimilars Average Price by Region (2018-2023) & (USD/Unit)
    Table 67. Global Insulin Biosimilars Average Price by Region (2024-2029) & (USD/Unit)
    Table 68. Global Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
    Table 69. Global Insulin Biosimilars Sales Quantity by Type (2024-2029) & (K Units)
    Table 70. Global Insulin Biosimilars Consumption Value by Type (2018-2023) & (USD Million)
    Table 71. Global Insulin Biosimilars Consumption Value by Type (2024-2029) & (USD Million)
    Table 72. Global Insulin Biosimilars Average Price by Type (2018-2023) & (USD/Unit)
    Table 73. Global Insulin Biosimilars Average Price by Type (2024-2029) & (USD/Unit)
    Table 74. Global Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
    Table 75. Global Insulin Biosimilars Sales Quantity by Application (2024-2029) & (K Units)
    Table 76. Global Insulin Biosimilars Consumption Value by Application (2018-2023) & (USD Million)
    Table 77. Global Insulin Biosimilars Consumption Value by Application (2024-2029) & (USD Million)
    Table 78. Global Insulin Biosimilars Average Price by Application (2018-2023) & (USD/Unit)
    Table 79. Global Insulin Biosimilars Average Price by Application (2024-2029) & (USD/Unit)
    Table 80. North America Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
    Table 81. North America Insulin Biosimilars Sales Quantity by Type (2024-2029) & (K Units)
    Table 82. North America Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
    Table 83. North America Insulin Biosimilars Sales Quantity by Application (2024-2029) & (K Units)
    Table 84. North America Insulin Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
    Table 85. North America Insulin Biosimilars Sales Quantity by Country (2024-2029) & (K Units)
    Table 86. North America Insulin Biosimilars Consumption Value by Country (2018-2023) & (USD Million)
    Table 87. North America Insulin Biosimilars Consumption Value by Country (2024-2029) & (USD Million)
    Table 88. Europe Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
    Table 89. Europe Insulin Biosimilars Sales Quantity by Type (2024-2029) & (K Units)
    Table 90. Europe Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
    Table 91. Europe Insulin Biosimilars Sales Quantity by Application (2024-2029) & (K Units)
    Table 92. Europe Insulin Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
    Table 93. Europe Insulin Biosimilars Sales Quantity by Country (2024-2029) & (K Units)
    Table 94. Europe Insulin Biosimilars Consumption Value by Country (2018-2023) & (USD Million)
    Table 95. Europe Insulin Biosimilars Consumption Value by Country (2024-2029) & (USD Million)
    Table 96. Asia-Pacific Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
    Table 97. Asia-Pacific Insulin Biosimilars Sales Quantity by Type (2024-2029) & (K Units)
    Table 98. Asia-Pacific Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
    Table 99. Asia-Pacific Insulin Biosimilars Sales Quantity by Application (2024-2029) & (K Units)
    Table 100. Asia-Pacific Insulin Biosimilars Sales Quantity by Region (2018-2023) & (K Units)
    Table 101. Asia-Pacific Insulin Biosimilars Sales Quantity by Region (2024-2029) & (K Units)
    Table 102. Asia-Pacific Insulin Biosimilars Consumption Value by Region (2018-2023) & (USD Million)
    Table 103. Asia-Pacific Insulin Biosimilars Consumption Value by Region (2024-2029) & (USD Million)
    Table 104. South America Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
    Table 105. South America Insulin Biosimilars Sales Quantity by Type (2024-2029) & (K Units)
    Table 106. South America Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
    Table 107. South America Insulin Biosimilars Sales Quantity by Application (2024-2029) & (K Units)
    Table 108. South America Insulin Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
    Table 109. South America Insulin Biosimilars Sales Quantity by Country (2024-2029) & (K Units)
    Table 110. South America Insulin Biosimilars Consumption Value by Country (2018-2023) & (USD Million)
    Table 111. South America Insulin Biosimilars Consumption Value by Country (2024-2029) & (USD Million)
    Table 112. Middle East & Africa Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
    Table 113. Middle East & Africa Insulin Biosimilars Sales Quantity by Type (2024-2029) & (K Units)
    Table 114. Middle East & Africa Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
    Table 115. Middle East & Africa Insulin Biosimilars Sales Quantity by Application (2024-2029) & (K Units)
    Table 116. Middle East & Africa Insulin Biosimilars Sales Quantity by Region (2018-2023) & (K Units)
    Table 117. Middle East & Africa Insulin Biosimilars Sales Quantity by Region (2024-2029) & (K Units)
    Table 118. Middle East & Africa Insulin Biosimilars Consumption Value by Region (2018-2023) & (USD Million)
    Table 119. Middle East & Africa Insulin Biosimilars Consumption Value by Region (2024-2029) & (USD Million)
    Table 120. Insulin Biosimilars Raw Material
    Table 121. Key Manufacturers of Insulin Biosimilars Raw Materials
    Table 122. Insulin Biosimilars Typical Distributors
    Table 123. Insulin Biosimilars Typical Customers
List of Figures
    Figure 1. Insulin Biosimilars Picture
    Figure 2. Global Insulin Biosimilars Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Insulin Biosimilars Consumption Value Market Share by Type in 2022
    Figure 4. Rapid-Acting Biosimilars Examples
    Figure 5. Long-Acting Biosimilars Examples
    Figure 6. Premixed Biosimilars Examples
    Figure 7. Global Insulin Biosimilars Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 8. Global Insulin Biosimilars Consumption Value Market Share by Application in 2022
    Figure 9. Type I Diabetes Examples
    Figure 10. Type II Diabetes Examples
    Figure 11. Global Insulin Biosimilars Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 12. Global Insulin Biosimilars Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 13. Global Insulin Biosimilars Sales Quantity (2018-2029) & (K Units)
    Figure 14. Global Insulin Biosimilars Average Price (2018-2029) & (USD/Unit)
    Figure 15. Global Insulin Biosimilars Sales Quantity Market Share by Manufacturer in 2022
    Figure 16. Global Insulin Biosimilars Consumption Value Market Share by Manufacturer in 2022
    Figure 17. Producer Shipments of Insulin Biosimilars by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
    Figure 18. Top 3 Insulin Biosimilars Manufacturer (Consumption Value) Market Share in 2022
    Figure 19. Top 6 Insulin Biosimilars Manufacturer (Consumption Value) Market Share in 2022
    Figure 20. Global Insulin Biosimilars Sales Quantity Market Share by Region (2018-2029)
    Figure 21. Global Insulin Biosimilars Consumption Value Market Share by Region (2018-2029)
    Figure 22. North America Insulin Biosimilars Consumption Value (2018-2029) & (USD Million)
    Figure 23. Europe Insulin Biosimilars Consumption Value (2018-2029) & (USD Million)
    Figure 24. Asia-Pacific Insulin Biosimilars Consumption Value (2018-2029) & (USD Million)
    Figure 25. South America Insulin Biosimilars Consumption Value (2018-2029) & (USD Million)
    Figure 26. Middle East & Africa Insulin Biosimilars Consumption Value (2018-2029) & (USD Million)
    Figure 27. Global Insulin Biosimilars Sales Quantity Market Share by Type (2018-2029)
    Figure 28. Global Insulin Biosimilars Consumption Value Market Share by Type (2018-2029)
    Figure 29. Global Insulin Biosimilars Average Price by Type (2018-2029) & (USD/Unit)
    Figure 30. Global Insulin Biosimilars Sales Quantity Market Share by Application (2018-2029)
    Figure 31. Global Insulin Biosimilars Consumption Value Market Share by Application (2018-2029)
    Figure 32. Global Insulin Biosimilars Average Price by Application (2018-2029) & (USD/Unit)
    Figure 33. North America Insulin Biosimilars Sales Quantity Market Share by Type (2018-2029)
    Figure 34. North America Insulin Biosimilars Sales Quantity Market Share by Application (2018-2029)
    Figure 35. North America Insulin Biosimilars Sales Quantity Market Share by Country (2018-2029)
    Figure 36. North America Insulin Biosimilars Consumption Value Market Share by Country (2018-2029)
    Figure 37. United States Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 38. Canada Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 39. Mexico Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 40. Europe Insulin Biosimilars Sales Quantity Market Share by Type (2018-2029)
    Figure 41. Europe Insulin Biosimilars Sales Quantity Market Share by Application (2018-2029)
    Figure 42. Europe Insulin Biosimilars Sales Quantity Market Share by Country (2018-2029)
    Figure 43. Europe Insulin Biosimilars Consumption Value Market Share by Country (2018-2029)
    Figure 44. Germany Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 45. France Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 46. United Kingdom Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 47. Russia Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 48. Italy Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 49. Asia-Pacific Insulin Biosimilars Sales Quantity Market Share by Type (2018-2029)
    Figure 50. Asia-Pacific Insulin Biosimilars Sales Quantity Market Share by Application (2018-2029)
    Figure 51. Asia-Pacific Insulin Biosimilars Sales Quantity Market Share by Region (2018-2029)
    Figure 52. Asia-Pacific Insulin Biosimilars Consumption Value Market Share by Region (2018-2029)
    Figure 53. China Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 54. Japan Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 55. Korea Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 56. India Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 57. Southeast Asia Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 58. Australia Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 59. South America Insulin Biosimilars Sales Quantity Market Share by Type (2018-2029)
    Figure 60. South America Insulin Biosimilars Sales Quantity Market Share by Application (2018-2029)
    Figure 61. South America Insulin Biosimilars Sales Quantity Market Share by Country (2018-2029)
    Figure 62. South America Insulin Biosimilars Consumption Value Market Share by Country (2018-2029)
    Figure 63. Brazil Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 64. Argentina Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 65. Middle East & Africa Insulin Biosimilars Sales Quantity Market Share by Type (2018-2029)
    Figure 66. Middle East & Africa Insulin Biosimilars Sales Quantity Market Share by Application (2018-2029)
    Figure 67. Middle East & Africa Insulin Biosimilars Sales Quantity Market Share by Region (2018-2029)
    Figure 68. Middle East & Africa Insulin Biosimilars Consumption Value Market Share by Region (2018-2029)
    Figure 69. Turkey Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 70. Egypt Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 71. Saudi Arabia Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 72. South Africa Insulin Biosimilars Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 73. Insulin Biosimilars Market Drivers
    Figure 74. Insulin Biosimilars Market Restraints
    Figure 75. Insulin Biosimilars Market Trends
    Figure 76. Porters Five Forces Analysis
    Figure 77. Manufacturing Cost Structure Analysis of Insulin Biosimilars in 2022
    Figure 78. Manufacturing Process Analysis of Insulin Biosimilars
    Figure 79. Insulin Biosimilars Industrial Chain
    Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 81. Direct Channel Pros & Cons
    Figure 82. Indirect Channel Pros & Cons
    Figure 83. Methodology
    Figure 84. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Insulin Biosimilars Supply, Demand and Key Producers, 2023-2029

Global Insulin Biosimilars Supply, Demand and Key Producers, 2023-2029

date 01 Feb 2023

date Pharma & Healthcare

The global Insulin Biosimilars market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Insulin Biosimilars Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Insulin Biosimilars Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Insulin Biosimilars market size was valued at USD 1522.8 million in 2023 and is forecast to a readjusted size of USD 1917.9 million by 2030 with a CAGR of 3.3% during review period.

Product Tags

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>